Affiliations: [a] Department of Urology, Charité – Universitätsmedizin Berlin, Berlin, Germany | [b] Berlin Institute for Urologic Research, Berlin, Germany | [c] Department of Urology, Sana Medical Center Offenbach, Offenbach/Main, Germany | [d] Max Delbrueck Center for Molecular Medicine in the Helmholtz Association, Cancer Research Program, Berlin, Germany | [e] Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK
Correspondence:
[*]
Corresponding author: Angelika Tölle, Department of Urology, Charité – Universitätsmedizin Berlin, Berlin 10117, Germany. Tel.: +49 30 450 515040; Fax: +49 30 450 515904; E-mail: angelika.toelle@charite.de.
Abstract: BACKGROUND: There is an urgent need for better prostate cancer (PCa) biomarkers due to the low specificity of prostate specific antigen (PSA). OBJECTIVE: Prostate Health Index (PHI) is an advanced PSA-based test for early detection of PCa. The present study aim was to investigate the potential improvement of diagnostic accuracy of PHI by its combination with suitable discriminative microRNAs (miRNAs). METHODS: A two-phase study was performed. In a discovery phase, a panel of 177 miRNAs was measured in ten men with biopsy proven PCa and ten men with histologically no evidence of malignancy (NEM). These results were validated in a second phase including 25 patients in each group. The patients of all groups were matched regarding their PSA values and PHI were measured. RESULTS: Based on data in the discovery phase, four elevated miRNAs were selected as potential miRNA candidates for further validation. A combination of miR-222-3p as the best discriminative miRNA with PHI extended the diagnostic accuracy of PHI from an AUC value of 0.690 to 0.787 and resulted in a sensitivity of 72.0% and a specificity of 84.0%. CONCLUSION: Circulating microRNAs show useful diagnostic potential in combination with common used biomarkers to enhance their diagnostic power.
